CD14 and COVID-19: (142) studied a cohort of 33 hospitalized patients diagnosed with COVID-19 and observed that the counts of CD16+ monocytes (including non-classical CD14+CD16++ and intermediate pro-inflammatory CD14++CD16+ subpopulations with high expression of IL-6) were significantly increased, especially in patients who developed ARDS.